[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"mild-neurocognitive-disorder\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:mild-neurocognitive-disorder":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,45,83,105],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100570302","phase-2-pramipexole-versus-escitalopram-to-treat-major-depressive-disorder-mdd-and-comorbid-mdd-with-mild-neurocognitive-disorder-mnd-in-persons-with-hiv-100570302",false,"NCT06705478","Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV","An Open-Label, Randomized Controlled Trial of Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV","Inclusion Criteria:\n\n* Documented HIV-1 infection.\n* Diagnosis of MDD.\n* On current ART regimen for at least 90 days prior to study entry with no interruption in treatment greater than 7 consecutive days.\n* No plans to change ART while on study.\n* Plasma HIV-1 RNA levels of less than 200 copies\u002FmL obtained within 90 days prior to enrollment.\n* Study candidates previously treated for depression are eligible provided the study candidate's last dose of antidepressant taken is at least 4 weeks prior to study entry, with the exception of fluoxetine, which the last dose taken must have been at least 8 weeks prior to study entry.\n* Laboratory values obtained within 30 days prior to study entry that meet protocol criteria as determined by the site investigator of record.\n* Study candidates of child-bearing potential must have a negative serum or urine pregnancy test performed at screening and within 2 days prior to study entry.\n* Study candidates of child-bearing potential who are participating in sexual activity that could lead to pregnancy must agree to use at least one highly effective method for contraception.\n\nExclusion Criteria:\n\n* Active suicidality, and\u002For severe MDD, psychotic disorders, manic or hypomanic symptoms occurring in the context of bipolar disorder type I or II, or cyclothymic disorder, or another current Axis I diagnosis judged by the investigator to interfere with the trial.\n* Study candidate self-report of depressive symptoms that have persisted for over 50 percent of waking hours and for over 50 percent of days over the 24 months prior to study entry.\n* Severe, active alcohol or substance use disorder by DSM-5-TR criteria in the 6 months prior to study entry.\n* Active alcohol or substance use judged by the investigator to interfere with the trial.\n* Any acute infection within 14 days prior to study entry.\n* Acute or serious illness requiring systemic treatment and\u002For hospitalization within 90 days prior to study entry.\n* Active coronary artery disease (CAD) or myocardial infarction (MI) within 180 days prior to study entry.\n* Presence of rheumatoid arthritis, Sjogren's syndrome, systemic lupus erythematosus (SLE), dermatomyositis, ulcerative colitis, Crohn's disease, or other chronic inflammatory conditions.\n* Immune reconstitution inflammatory syndrome (IRIS) or a history of IRIS within 180 days prior to study entry.\n* Unstable or advanced liver disease.\n* Receipt of medications judged by the site investigator to significantly influence depression or neurocognitive function within 30 days prior to study entry.\n* Non-HIV-associated neurological disorder comorbidity.\n* Diagnosis of epilepsy with antiepileptic drug treatment.\n* Untreated HCV infection and HCV viremia.\n* Current CNS malignant tumor or CNS opportunistic infection (OI).\n* Current systemic malignant tumor or of a current systemic AIDS-defining OI.\n* History of completed treatment of CNS or systemic malignant tumor within the 5 years prior to study entry.\n* History of completed treatment of CNS OI within the 5 years prior to study entry.\n* Documented history of completed treatment of systemic AIDS-defining OI, as well as Mycobacterium Tuberculosis Infection, within the 180 days prior to study entry.\n* New diagnosis of syphilis or treatment for syphilis within the 180 days prior to study entry.\n* History of neurosyphilis.\n* Severe chronic obstructive pulmonary disease.\n* Congestive heart failure (CHF).\n* Use of systemic steroids daily (except testosterone).\n* Diseases that cause a known bleeding diathesis.\n* Immunostimulant therapies and trials of non-FDA-approved ARV medications within 30 days prior to study entry.\n* Immunosuppressive medications if judged by the investigator to affect study outcomes.\n* Currently pregnant, planning to become pregnant during the study period, or currently breastfeeding.\n* Known allergy\u002Fsensitivity or any hypersensitivity to the study drugs or their formulations.\n* Study candidates on prohibited medications at the time of screening will be excluded from study participation.\n\nInclusion Criteria for Participants at US Sites Who Consent to the Lumbar Puncture (LP) Procedure:\n\n* Non-focal neurological examination. Study candidates with focal findings should have expert assessment for mass effect prior to the LP.\n* Laboratory values that meet LP protocol criteria as determined by the site investigator.\n\nExclusion Criteria for Participants at US Sites who Consent to the LP Procedure:\n\n* Current use of anti-coagulants.\n* Known presence of intracerebral mass or lesion that is judged to affect the safety of an LP.\n* Known presence of an active CNS infection that could alter CNS\u002FCSF inflammatory measures.\n* Known allergy to lidocaine.\n* Individuals who are unable to safely tolerate an LP due to physical limitation or condition.\n* Body mass index (BMI) greater than 40 kg\u002Fm\\^2.","ALL","18 Years","70 Years",{"count":20,"type":21},186,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","A phase II, randomized, open-label, two-arm clinical trial evaluating the safety and efficacy of pramipexole extended release (ER) versus escitalopram for the treatment of major depressive disorder (MDD) and comorbid MDD with mild neurocognitive disorder (MND) in persons with HIV (PWH). Participants will be assessed comprehensively and briefly at intercurrent visits to monitor for toxicity, response to therapy, and to assess for dose changes.\n\nAn optional sub-study to evaluate treatment impact on the cerebrospinal fluid (CSF) profile will be conducted in a subset of 36 participants.",[27,28,29],"Major Depressive Disorder","Mild Neurocognitive Disorder","HIV",[31],"Comorbid MND","RECRUITING","2026-06-12",{"date":35,"type":36},"2026-06-15","ACTUAL",{"date":38,"type":36},"2026-05-17",{"date":40,"type":21},"2026-12-02",{"name":42,"class":43},"National Institute of Allergy and Infectious Diseases (NIAID)","NIH",41,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":59,"conditions":60,"keywords":65,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":82},"100633442","brain-stimulation-and-cognitive-training-for-mci-100633442","NCT07526740","Brain Stimulation and Cognitive Training for MCI","Combining Brain Stimulation With Computerized Cognitive Training for MCI","RISE pilot","Inclusion Criteria:\n\n1. Age 60-85 (inclusive).\n2. English as a first\u002Fprimary language.\n3. Adequate sensorimotor function and verbal expressive abilities to complete all assessments.\n4. Must have a co-participant (e.g. spouse, adult child or relative, sibling, cohabitator, friend, caregiver) who has at least weekly in-person contact with the participant and is willing to participate in the study as a collateral informant.\n5. Meets the following requirements for current and prior medications and treatments:\n\n   1. Is on fixed pharmacotherapy (i.e. stable dose of medication\u002Fs) for ≥ 4 weeks before enrollment. This includes, but is not limited to, cholinesterase inhibitors, NMDA receptor antagonists, and antidepressants.\n   2. Anti-amyloid monoclonal antibody therapy for AD\u002FMCI:\n\n      * Prior treatment is permitted if last infusion occurred ≥ 8 weeks before enrollment.\n      * Current treatment is permitted if the dose has been stable for ≥ 12 weeks before enrollment, with no planned dose change during study participation.\n   3. Prior TMS treatment is permitted if the last stimulation session was ≥ 24 weeks before enrollment.\n6. Documented diagnosis of MCI per NIA-AA criteria or Mild Neurocognitive Disorder per DSM-5 criteria by a healthcare provider within the past year, with a presumed etiology of possible or probable AD 7. Met actuarial neuropsychological criteria for MCI43 within the past year (i.e. ≥2 impaired scores within one cognitive domain, or ≥1 impaired scores in ≥3 domains, where an impaired score is defined as ≤16th percentile using appropriate demographically-corrected norms).\n\nExclusion Criteria:\n\n1. Telephone Interview for Cognitive Status (TICS) score of ≤ 22 suggestive of dementia.\n2. Prior diagnosis of Dementia (NIA-AA) or Major Neurocognitive Disorder (DSM-5).\n3. Daily\u002Fweekly anticholinergic or sedative use. Stimulants may be allowed pending investigator review.\n4. History of significant or unstable condition\u002Fs or treatments for these condition\u002Fs that may impact cognition (as determined by the study investigators) such as significant cardiac (e.g. heart failure), infectious (e.g. HIV, urinary tract infection), or metabolic disease (e.g. labile diabetes), cancer (e.g. brain cancer, chemotherapy-induced cognitive impairment), severe mental illness (e.g., bipolar disorder, psychoses), alcohol or substance use disorder, developmental disorder (e.g. autism spectrum disorder, intellectual disability), or other neurologic disease (e.g. movement disorder, multiple sclerosis, moderate to severe brain injury, seizures).\n5. Plan to initiate treatment for AD\u002FMCI with monoclonal antibody therapy during study participation.\n6. For those currently receiving monoclonal antibody therapy, documented history of clinically significant amyloid-related imaging abnormalities (ARIA) in their medical record.\n7. Current use of any implanted brain stimulation device.\n8. Enrolled in a clinical trial or has received an investigational medication or device in the last 30 days that may impact cognition or mood.\n9. MRI contraindications (e.g., ferromagnetic implants, claustrophobia).\n10. Unable or unwilling to engage in BrainHQ activities.\n11. TMS contraindications (e.g., ferromagnetic implants, conditions or treatments that lower seizure threshold, taking medications that have short half-lives) or no identifiable motor threshold.","60 Years","85 Years",{"count":56,"type":21},50,[58],"NA","This is a randomized clinical trial of a treatment that combines non-invasive brain stimulation with computerized cognitive training (CCT) for people with mild cognitive impairment (MCI). The form of brain stimulation used in this study is accelerated intermittent theta burst stimulation (iTBS). All participants receive the same amount of iTBS and are randomly assigned to engage in one of two types of CCT. The goals of the study are to see if this combined treatment is feasible and acceptable to people with MCI and whether combined iTBS and CCT improves memory, thinking skills, mood, and daily function.",[61,28,62,63,64],"Mild Cognitive Impairment (MCI)","Neurocognitive Disorders","Cognitive Dysfunction","Cognition Disorders",[66,67,68,69,70,71],"Aging","Alzheimers","Memory Loss","Mild Cognitive Impairment","Transcranial Magnetic Stimulation","cognitive training","2026-05-20",{"date":74,"type":36},"2026-05-22",{"date":76,"type":36},"2026-03-16",{"date":78,"type":21},"2030-05-31",{"name":80,"class":81},"Medical University of South Carolina","OTHER",1,{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":87,"acronym":4,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":89,"targetDuration":4,"studyType":22,"phases":91,"briefSummary":92,"conditions":93,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":82},"100527109","endovascular-therapy-versus-best-medical-treatment-for-acute-large-vessel-occlusion-stroke-with-low-nihss-100527109","NCT06143488","Endovascular Therapy Versus Best Medical Treatment for Acute Large Vessel Occlusion Stroke With Low NIHSS","1. Aged 18 years or older;\n2. The time from onset of acute ischemic stroke to arterial puncture is within 24 hours. Onset time is defined as the patient's Last Known Well (LKW);\n3. Low NIHSS score (2-5 points), with at least one of the following items:\n\n   1. Altered mental status (lethargy or worse);\n   2. Facial palsy (facial weakness score ≥ 1 point);\n   3. Motor dysfunction (limb weakness score ≥ 1 point);\n   4. Aphasia (language disturbance score ≥ 1 point);\n   5. Hemispatial neglect (neglect score ≥ 1 point);\n4. Intracranial internal carotid artery, proximal M1 or M2 segment of middle cerebral artery occlusion (excluding tandem lesions) confirmed by cerebral CTA\u002FMRA\u002FDSA before randomization, which is identified as the culprit vessel for stroke;\n5. All patients receive CTP\u002FMR perfusion imaging, with a volume of perfusion delay (Tmax\\>6 s) ≥ 50 mL;\n6. Written informed consent is obtained from the patient or legal surrogate, with agreement for long-term follow-up.",{"count":90,"type":21},264,[58],"Patients presenting with mild symptoms of acute ischemic stroke are common and account for approximately half of all acute ischemic stroke. About 30% of patients with minor stroke have a 90-day functional disability. Radiologically proven a large vessel occlusion (LVO) in patients with minor stroke is a well-established predictor of poor outcomes, while the poor outcomes following best medical management in patients with minor stroke with the underlying presence of a LVO are mainly driven by the occurrence of early neurological deterioration (END).\n\nConsidering the well-known strong association between lack of arterial recanalization and END, endovascular therapy (EVT) appears as an attractive option to improve functional outcomes for LVO-related patients with stroke with mild symptoms. Whether EVT is safe and effective in patients with mild stroke with an LVO is currently debated, since these patients were typically excluded from the pivotal EVT trials.\n\nThe current study aimed to further test the hypothesis that endovascular therapy would be superior to medical management with respect to functional recovery among low NIHSS patients caused by acute large-vessel occlusion in the anterior circulation.",[94,28,95],"Acute Ischemic Stroke","Thrombectomy","2026-04-27",{"date":98,"type":36},"2026-04-30",{"date":100,"type":36},"2024-02-07",{"date":102,"type":21},"2028-03-31",{"name":104,"class":81},"First Affiliated Hospital of Wannan Medical College",{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":111,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":113,"enrollmentInfo":114,"targetDuration":4,"studyType":22,"phases":116,"briefSummary":117,"conditions":118,"keywords":119,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":82},"100595926","deep-rtms-for-mild-neurocognitive-disorder-in-older-adults-100595926","NCT07038798","Deep rTMS for Mild Neurocognitive Disorder in Older Adults","Feasibility and Tolerability of Deep Repetitive Transcranial Magnetic Stimulation for Mild Neurocognitive Disorder in Older Adults: A Pilot Study (DeepMIND)","Deep MIND","Inclusion Criteria:\n\n* 60 - 90 years old\n* Able to provide informed consent to participate in the study\n* Subjective concern of mild decline in cognitive function over the past year\n* Mild impairment in cognitive performance\n* Preserved independence in everyday activities\n* Independently mobile (e.g., participants must be able to get in and out of a chair on their own)\n* Participants will be required to be on stable dosages of other psychotropic medications for at least 4 weeks prior to screening\n\nExclusion Criteria:\n\n* Currently receiving treatment or subjective need for treatment for bipolar I or II disorder; psychotic disorder\n* Active suicidal behavior\n* Severe depression and\u002For anxiety\n* Other neurological or psychiatric disorders accounting for the cognitive deficits\n* Impairment in basic and\u002For instrumental activities of daily living\n* Substance use disorder (other than tobacco use disorder) in the past 3 months before entering the study\n* Traditional contraindications to rTMS: Intracranial or metal implants in the head or nearby regions, excluding the mouth, that cannot be safely removed; History of epilepsy or seizures; Active unstable medical condition (recent laboratory and neuroimaging alterations, delirium); Pacemaker and\u002For implantable cardioverter-defibrillators; current use of bupropion, treatment with equivalent benzodiazepine dose to lorazepam \\>2 mg\u002Fday\n* People with severe literacy, visual, or hearing issues that affect the ability to engage in the interviews\n* People with recurring migraines or headaches (weekly or more)\n* Frequent dizziness\u002Fvertigo\n* Individuals residing beyond the borders of the Greater Hamilton Area and its neighbouring vicinities","90 Years",{"count":115,"type":21},30,[58],"This study aims to: (1) assess the feasibility and tolerability of three deep transcranial magnetic stimulation (dTMS) coils H1, H4, and H7 in older adults with mild neurocognitive disorder (mild NCD); and (2) evaluate changes in cognition through neuropsychological testing, brain activity through EEG, and mood and sleep through self-report questionnaires. Participants will be assigned to one of three arms: H1- coil vs. H4-coil vs. H7-coil, and all participants will complete assessments examining dTMS side effects, mental health symptoms, and cognition. EEG, questionnaires, and CNS vital signs will be measured at baseline, midpoint (after 10th session- before dTMS treatment on visit 11), and end point, as well as follow up. Collectively, the study will address the absolute and differential feasibility and tolerability of the H1, H4 and H7 coils to provide preliminary data for a future randomized controlled trial comparing this novel intervention to a sham stimulation (placebo) control.",[28],[28,120,69,121,122,123,124,125,126,127,128],"Mild NCD","Deep Transcranial Magnetic Stimulation","deep TMS","dTMS","H coil","H-coil","H1-coil","H4-coil","H7-coil","2025-09-30",{"date":131,"type":36},"2025-10-06",{"date":133,"type":36},"2025-08-26",{"date":135,"type":21},"2027-01",{"name":137,"class":81},"St. Joseph's Healthcare Hamilton"]